Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Has Average Price Target of $355.38 According to Analysts

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $355.38.

A number of research analysts have weighed in on LGND shares. Weiss Ratings lowered Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research note on Monday, November 2nd. Citigroup lifted their price objective on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Barclays upped their target price on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, November 11th. HC Wainwright reissued a “buy” rating and set a $358.00 price objective on shares of Ligand Pharmaceuticals in a research note on Thursday, September 24th. Finally, Oppenheimer restated an “outperform” rating and set a $326.00 price objective (up from $285.00) on shares of Ligand Pharmaceuticals in a report on Monday, August 3rd.

Check Out Our Latest Research Report on LGND

Insider Buying and Selling at Ligand Pharmaceuticals

In related news, Director Jason Aryeh sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $320.05, for a total value of $960,150.00. Following the transaction, the director owned 105,476 shares in the company, valued at approximately $33,757,593.80. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Andrew Reardon sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $313.22, for a total transaction of $1,566,100.00. Following the completion of the transaction, the insider directly owned 31,854 shares in the company, valued at approximately $9,977,309.88. This represents a 13.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 24,093 shares of company stock worth $7,384,287 in the last quarter. Company insiders own 5.60% of the company’s stock.

Institutional Investors Weigh In On Ligand Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new position in Ligand Pharmaceuticals during the second quarter worth $27,000. Jacobi Capital Management LLC acquired a new position in Ligand Pharmaceuticals during the 3rd quarter valued at $31,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Ligand Pharmaceuticals in the 2nd quarter valued at $75,000. MCF Advisors LLC boosted its holdings in Ligand Pharmaceuticals by 118.9% in the 2nd quarter. MCF Advisors LLC now owns 243 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 132 shares during the period. Finally, Covestor Ltd boosted its holdings in Ligand Pharmaceuticals by 49.8% in the 3rd quarter. Covestor Ltd now owns 337 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 112 shares during the period. Hedge funds and other institutional investors own 91.28% of the company’s stock.

Ligand Pharmaceuticals Price Performance

Ligand Pharmaceuticals stock opened at $286.94 on Tuesday. The stock has a market capitalization of $5.74 billion, a P/E ratio of 128.10, a P/E/G ratio of 5.22 and a beta of 1.16. Ligand Pharmaceuticals has a 12-month low of $175.89 and a 12-month high of $326.63. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19. The firm’s 50-day moving average is $302.30 and its two-hundred day moving average is $260.05.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The business had revenue of $78.75 million during the quarter, compared to analyst estimates of $77.00 million. During the same quarter in the previous year, the business posted $3.09 earnings per share. The company’s revenue was down 31.8% on a year-over-year basis. Equities analysts predict that Ligand Pharmaceuticals will post 2.35 earnings per share for the current year.

Ligand Pharmaceuticals Company Profile

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Further Reading

Analyst Recommendations for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.